SR
Therapeutic Areas
Cocrystal Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CC-42344 (Oral PB2 inhibitor) | Influenza A | Phase 2 |
| CC-42344 (Inhaled PB2 inhibitor) | Influenza A | Phase 1 |
| CDI-988 (Oral Pan-viral protease inhibitor) | Norovirus | Phase 1 |
| Pan-viral protease inhibitor | Rhinovirus | Discovery/Preclinical |
| Oral replication inhibitor | Influenza A & B | Discovery/Preclinical |
Leadership Team at Cocrystal Pharma
SL
Sam Lee, Ph.D.
Co-Chief Executive Officer and President
JJ
James J. Martin
Co-Chief Executive Officer and Chief Financial Officer
RK
Roger Kornberg, Ph.D.
Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
PF
Phillip Frost, M.D.
Director
FH
Fred Hassan
Director